effect of retraining on treatment success, quality of life, and metabolic parameters in patients with type 1 diabetes using an insulin pump

Objective:To investigate the effect of insulin pump user retraining on treatment success, quality of life, and metabolic parameters of patients with type 1 diabetes using continuous subcutaneous insulin infusion

Subjects and Methods: A total of 35 subjects participated in this prospective study. All patients were given insulin pump user retraining. Their knowledge level and application skills, metabolic parameters, quality of life, and satisfaction from treatment were evaluated at baseline and after 6 months

Results: There was significant improvement in patients' knowledge and application skills after insulin pump user retraining [self-assess-ment of user skills: 69.7 +/-11.5 vs. 76.3 +/- 11.3, p < 0.001; knowledge level on technical issues: 3.3 +/- 1.1 vs. 4.1 +/- 1.8, p = 0.003; glucose monitoring: 27.1 +/- 5.8 vs. 29.2 +/- 5.6, p = 0.006; management of hyperglycemia: 13.1 +/- 3.2 vs. 15.7 +/- 3.4, p < 0.001; management of pump and infusion site problems: 8.8 +/- 2.6 vs. 10.6 +/- 2.6, p = 0.001]. Hemoglobin [Hb]A[ic] levels of patients with poor glycemic control improved after retraining [8.61 % +/- 0.78 vs. 8.23% +/- 0.79, p = 0.02]. However, no significant improvement in quality of life and treatment satisfaction parameters were found

Conclusion: Management of type 1 diabetes in insulin pump users can be significantly improved by retraining. Even a basic short-term retraining program helps patients to increase their knowledge level and ability to more effectively use the insulin pump. The fact that retraining significantly improves glycemic parameters in patients with poor metabolic control indicates that priority should be given to this group of patients. Further studies with individualized training programs i larger sample sizes with long-term follow-up are needed 1 establish the importance of retraining and create re-educ. tion plans for patients with type 1 diabetes using an insuli pump

Effect of levothyroxine suppression therapy on plasma thrombin activatable fibrinolysis inhibitor antigen levels in benign thyroid nodules

The aim of this prospective study was to investigate the effect of LT4 suppression therapy on plasma thrombin activatable fibrinolysis inhibitor [TAFI] antigen and plasminogen activator inhibitor-1 [PAI-1] levels in benign thyroid nodules. We also compared hyperthyroid patients and healthy controls. Twenty premenopausal women with benign thyroid nodules were given LT4 suppression therapy for 1 year. Plasma TAFI and PAI-1 antigen levels were measured at baseline and after LT4 suppression treatment. The endogenous hyperthyroid group was composed of 19 premenopausal females with newly diagnosed endogenous hyperthyroidism. Eighteen age-matched euthyroid healthy premenopausal women were enrolled as the control group. TAFI antigen levels decreased after LT4 suppression treatment; however, the difference was not statistically significant [p = 0.057]. LT4 treatment resulted in a nonsignificant increase in PAI-1 levels. Patients with endogenous hyperthyroidism had decreased levels of TAFI antigen and increased levels of PAI-1 antigen [p < 0.05]. There was a negative correlation between the FT4 and TAFI antigen levels. Serum TSH was positively correlated with the plasma levels of TAFI antigen. LT4 suppression therapy for benign thyroid nodules did not result in a significant decrease in TAFI antigen levels in premenopausal women, but endogenous hyperthyroidism was associated with significantly decreased levels of TAFI antigen

Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone

To evaluate subclinical inflammation and fibrinolysis in low-risk type 2 diabetic subjects and to assess the efficacy of metformin and rosiglitazone in this group Sixty-one normotensive, normoalbuminuric type 2 diabetic subjects without diabetes-related complications were included in a 4-week standardization period with glimepiride. After the standardization period, 21 subjects were excluded and the remaining 40 were randomly divided into two groups matched for age, gender, body mass index and disease duration. The first group [n = 20] received metformin [1,700 mg/day], the second group [n = 20] rosiglitazone [4 mg/day] for 12 weeks. Patients with low-density lipoprotein-cholesterol higher than 130 mg/dl at the beginning of the randomization period were treated with simvastatin [maximum dose 20 mg/day]. Twenty-three healthy controls were also recruited. Cytokine measurements were performed with ELISA kits Baseline plasma plasminogen activator inhibitor-1 [PAI-1] level of type 2 diabetic subjects was significantly elevated [p = 0.038], but baseline levels of soluble CD40 ligand [sCD40L] and thrombin-activatable fibrinolysis inhibitor-1 [TAFI] antigen did not differ from healthy controls. Twelve weeks of metformin or rosiglitazone therapy did not cause significant changes in sCD40L, PAI-1 and TAFI antigen levels. In simvastatin-treated subjects [n = 9] significant reductions of PAI-1 were achieved [p = 0.028], while sCD40L and TAFI-Ag did not differ from baseline values. Our results showed that nonobese diabetic patients at low cardiovascular risk had similar levels of subclinical markers of inflammation and fibrinolysis as matched healthy controls. Neither metformin nor rosiglitazone caused marked changes in sCD40L, PAI-1 and TAFI antigen levels. A subset of patients who received simvastatin showed a modest decrease in PAI-1 level and could contribute to beneficial vasculoprotective effect of the drug in type 2 diabetics

Plasma thiobarbituric acid-reactive substance levels in subclinical hypothyroidism

The purpose of this study was to determine thiobarbituric acid-reactive substance [TBARS] levels in subclinical hypothyroidism and to examine the effect of levothyroxine replacement on TBARS levels. A cohort of 28 female patients with subclinical hypothyroidism and 24 healthy controls were enrolled in this study. The levels of plasma TBARS, serum lipids, and high-sensitive C-reactive protein [CRP] in patients with subclinical hypothyroidism at baseline and after achieving euthyroid state by levothyroxine were assessed. TBARS levels of the patients were similar to those of the control group in the subclinical hypothyroid state and after restoration of euthyroidism by levothyroxine replacement. TBARS levels decreased after levothyroxine treatment, but did not reach statistical significance. There was no significant correlation between TBARS, lipid and CRP levels. Serum CRP levels were higher in subclinical hypothyroidism [4.28 +/- 0.9 mg/l] than in the control group [1.95 +/- 0.34 mg/l] and the difference was statistically significant [p = 0.03]. After achieving euthyroid state, CRP levels decreased significantly in patients with subclinical hypothyroidism from 4.28 +/- 0.9 to 2.32 +/- 0.6 mg/l [p = 0.006]. Our findings suggest that there is no significant alteration of plasma TBARS levels neither in subclinical hypothyroid state nor after achieving euthyroid state. Serum CRP level is higher in patients with subclinical hypothyroidism than in the control group. Normalization of thyroid state seems to effectively reduce serum CRP levels in subclinical hypothyroidism without any correlation with TBARS activity